AstraZeneca (LSE:AZN) Posted Positive Phase III Results For Three Cancer Drugs

What happened: AstraZeneca (LSE:AZN) reported positive Phase III data at the ESMO Congress 2026 on 23 October for sonesitatug vedotin, IMFINZI with neoadjuvant enfortumab vedotin, and TAGRISSO with savolitinib. Key numbers: Data presented 23 October at ESMO Congress 2026. Company valued at £198.9b. Cited fair value of £157. Why it matters: The results support the view that breadth in late-stage oncology could offset future patent expiries, though analysts have flagged pricing pressure and high ADC manufacturing capital expenditure as risks if returns fall short.

AstraZeneca (LSE:AZN) reported positive Phase III data at the ESMO Congress 2026 on 23 October for sonesitatug vedotin, IMFINZI with neoadjuvant enfortumab vedotin, and TAGRISSO with savolitinib.

The results support the view that breadth in late-stage oncology could offset future patent expiries, though analysts have flagged pricing pressure and high ADC manufacturing capital expenditure as risks if returns fall short.